CA
NZ
UK
AU
IND
US
…
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Spruce Biosciences, Inc. is a clinical-stage biopharmaceutical company developing therapies for rare endocrine and genetic diseases. Long-term growth may be driven by advancement of clinical programs toward approvals, partnerships or licensing, and commercialization in niche markets, which could appeal to investors if trials succeed.
Material risks include clinical or regulatory failure, limited operating history with recurring losses and likely need for additional financing, plus execution challenges in commercializing therapies for small patient populations.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -46.18M | -42.29M | -29.54M | -13.09M | -9.86M |
| Net income | -45.08M | -42.69M | -30.03M | -13.24M | -9.86M |
| Selling general administrative | 12.09M | 11.37M | 5.56M | 2.29M | 1.57M |
| Reconciled depreciation | 0.07M | 0.07M | 0.04M | 0.01M | 0.00M |
| Ebit | -47.28M | -42.07M | -29.42M | -13.11M | -9.86M |
| Ebitda | -45.76M | -41.95M | -29.22M | -13.01M | -9.86M |
| Depreciation and amortization | 1.52M | 0.12M | 0.20M | 0.10M | 0.00M |
| Non operating income net other | 1.52M | - | 0.20M | - | - |
| Operating income | -47.28M | -42.07M | -29.42M | -13.11M | -9.97M |
| Other operating expenses | 47.28M | 42.07M | 29.42M | 13.11M | 9.97M |
| Interest expense | 0.42M | 0.34M | 0.32M | 0.07M | 0.00M |
| Interest income | 1.52M | - | - | - | - |
| Net interest income | 1.10M | -0.34M | -0.32M | -0.07M | 0.00M |
| Income tax expense | -1.10M | 0.40M | 0.49M | 0.15M | 0.11M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 47.28M | 42.07M | 29.42M | 13.11M | 9.97M |
| Total other income expense net | 1.10M | -0.23M | -0.12M | 0.02M | 0.11M |
| Net income from continuing ops | -46.18M | -42.29M | -29.54M | -13.09M | -9.86M |
| Net income applicable to common shares | -46.18M | -42.29M | -29.54M | -13.09M | -9.86M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 103.95M | 85.65M | 126.49M | 162.88M | 4.69M |
| Other current assets | 5.84M | 1.21M | 0.40M | 0.28M | 0.51M |
| Total liab | 27.44M | 17.16M | 15.12M | 13.46M | 35.33M |
| Total stockholder equity | 76.51M | 68.49M | 111.37M | 149.43M | -30.64M |
| Other current liab | 14.35M | 9.40M | 5.69M | 3.58M | 1.17M |
| Common stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -197.23M | -149.31M | -103.13M | -60.84M | -31.30M |
| Other liab | - | 0.16M | 0.07M | 0.12M | 0.02M |
| Other assets | 0.00M | 0.64M | 0.51M | 0.00M | 0.04M |
| Cash | 96.34M | 24.49M | 42.75M | 157.15M | 3.92M |
| Total current liabilities | 24.46M | 12.45M | 8.87M | 9.76M | 4.30M |
| Current deferred revenue | 4.91M | - | - | - | - |
| Net debt | -91.73M | -18.31M | -36.58M | -151.02M | 0.52M |
| Short term debt | 1.87M | 1.62M | 0.36M | 2.55M | 1.25M |
| Short long term debt | 1.62M | 1.62M | - | 2.55M | 1.25M |
| Short long term debt total | 4.61M | 6.18M | 6.17M | 6.13M | 4.45M |
| Other stockholder equity | 273.74M | 218.35M | 214.69M | 210.27M | 0.66M |
| Property plant equipment | - | 1.40M | 1.62M | 1.79M | - |
| Total current assets | 102.18M | 83.61M | 91.89M | 160.40M | 4.65M |
| Long term investments | - | 0.00M | 32.46M | - | - |
| Net tangible assets | - | 68.49M | 111.37M | 149.43M | -30.64M |
| Short term investments | 0.00M | 54.59M | 46.22M | - | - |
| Long term debt | 1.72M | 3.29M | 4.88M | 1.92M | 3.19M |
| Accounts payable | 3.33M | 1.43M | 2.82M | 3.63M | 1.88M |
| Accumulated other comprehensive income | 0.00M | -0.56M | -0.18M | -162.88M | - |
| Common stock total equity | - | 0.00M | - | 0.00M | 0.00M |
| Retained earnings total equity | - | -149.31M | - | -60.84M | - |
| Non currrent assets other | 0.55M | 55.18M | 0.65M | 0.69M | 0.04M |
| Non current assets total | 1.76M | 2.04M | 34.59M | 2.49M | 0.04M |
| Capital lease obligations | 1.27M | 1.40M | 1.65M | 1.65M | - |
| Long term debt total | - | 3.29M | - | 1.92M | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 23.70M | -79.08M | -0.07M | -0.00M | -79.08M |
| Change to liabilities | 1.86M | 1.15M | 3.73M | -0.23M | 1.70M |
| Total cashflows from investing activities | 23.69M | -79.17M | -0.07M | -0.00M | -0.00M |
| Net borrowings | - | 0.23M | 0.23M | 4.50M | 4.50M |
| Total cash from financing activities | -0.24M | 0.64M | 181.03M | 12.43M | 12.43M |
| Change to operating activities | 2.53M | 0.81M | -2.57M | 0.49M | -0.51M |
| Net income | -46.18M | -42.29M | -29.54M | -13.09M | -9.86M |
| Change in cash | -18.23M | -114.40M | 153.44M | -0.19M | -8.57M |
| Begin period cash flow | 42.96M | 157.37M | 3.92M | 4.11M | 12.68M |
| End period cash flow | 24.73M | 42.96M | 157.37M | 3.92M | 4.11M |
| Total cash from operating activities | -41.68M | -35.88M | -27.52M | -12.62M | -8.57M |
| Issuance of capital stock | - | 0.00M | 183.89M | 7.94M | 0.00M |
| Depreciation | 0.07M | 0.07M | 0.04M | 0.01M | 0.00M |
| Sale purchase of stock | 0.08M | 0.13M | 93.40M | - | - |
| Other cashflows from financing activities | -0.32M | 5.28M | 84.78M | -0.00M | -0.01M |
| Change to netincome | 3.67M | 4.39M | 0.82M | 0.20M | 0.10M |
| Capital expenditures | 0.01M | 0.09M | 0.07M | 0.00M | 0.00M |
| Cash flows other operating | -1.12M | - | -2.82M | - | - |
| Cash and cash equivalents changes | -18.23M | - | 153.44M | - | - |
| Change in working capital | 1.13M | 1.96M | 1.16M | 0.26M | 1.19M |
| Stock based compensation | 3.63M | 3.96M | 0.76M | 0.20M | 0.10M |
| Other non cash items | -0.34M | 0.31M | 0.07M | 1.98M | - |
| Free cash flow | -41.69M | -35.97M | -27.59M | -12.62M | -8.57M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SPRB Spruce Biosciences, Inc. Common Stock |
-2.67 5.42% |
46.66 | - | - | 3.00 | 0.40 | 15.32 | 1.30 |
| NVO Novo Nordisk A/S |
-0.68 1.64% |
40.70 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-3.02 0.55% |
547.85 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
916.06 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
611 Gateway Boulevard, South San Francisco, CA, United States, 94080
415 655 4168
22
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael G. Grey | Exec. Chairman | 1953 |
| Mr. Samir M. Gharib CPA, CPA, M.B.A. | Pres & CFO | 1982 |
| Dr. Javier Szwarcberg M.D., M.P.H. | CEO & Director | 1970 |
| Dr. Ralph William Charlton III, M.D. | Chief Medical Officer | 1970 |
| Dr. Libbie Mansell M.B.A., Ph.D. | Chief Regulatory & Quality Officer | NA |
| Ms. P. J. Ramtin | Sr. VP of Bus. Operations | NA |
| Mr. Michael G. Grey | Executive Chairman | 1953 |
| Mr. Samir M. Gharib C.P.A., M.B.A. | President & CFO | 1982 |
| Ms. P. J. Ramtin | Senior Vice President of Business Operations | NA |
| Ms. Heidi Petersen M.P.H. | Senior Vice President of Regulatory & Quality | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.26%
Communication Services
-0.18%
Consumer Cyclical
-0.36%
Consumer Defensive
+0.07%
Energy
-0.01%
Financial Services
-0.26%
Financials
-2.20%
Healthcare
-0.55%
Industrials
-0.08%
Real Estate
-0.33%
Technology
-0.70%
Utilities
-0.41%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...